Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2010 Sep;54(9):3537-44.
doi: 10.1128/AAC.00183-10. Epub 2010 Jun 14.

Absence of association between piperaquine in vitro responses and polymorphisms in the pfcrt, pfmdr1, pfmrp, and pfnhe genes in Plasmodium falciparum

Affiliations

Absence of association between piperaquine in vitro responses and polymorphisms in the pfcrt, pfmdr1, pfmrp, and pfnhe genes in Plasmodium falciparum

Sébastien Briolant et al. Antimicrob Agents Chemother. 2010 Sep.

Abstract

We have analyzed the profiles of 23 of Plasmodium falciparum strains for their in vitro chemosusceptibilities to piperaquine (PPQ), dihydroartemisinin (DHA), chloroquine, monodesethylamodiaquine, quinine, mefloquine, lumefantrine, atovaquone, pyrimethamine, and doxycycline (DOX) in association with polymorphisms in genes involved in quinoline resistance (Plasmodium falciparum crt [pfcrt], pfmdr1, pfmrp, and pfnhe). The 50% inhibitory concentrations (IC(50)s) for PPQ ranged from 29 to 98 nM (geometric mean = 57.8 nM, 95% confidence interval [CI] = 51 to 65) and from 0.4 to 5.8 nM for DHA (geometric mean = 1.8 nM, 95% CI = 1.4 to 2.3). We found a significant positive correlation between the responses to PPQ and DHA (r(2) = 0.17; P = 0.0495) and between the responses to PPQ and DOX (r(2) = 0.41; P = 0.001). We did not find a significant association between the PPQ IC(50) (0.0525 < P < 0.9247) or the DHA IC(50) (0.0138 < P < 0.9018) and polymorphisms in the pfcrt, pfmdr1, pfmrp, and pfnhe-1 genes. There was an absence of cross-resistance with quinolines, and the IC(50)s for PPQ and DHA were found to be unrelated to mutations in the pfcrt, pfmdr1, pfmrp, and pfnhe-1 transport protein genes, which are involved in quinoline antimalarial drug resistance. These results confirm the interest in and the efficacy of the combination of PPQ and DHA for areas in which parasites are resistant to chloroquine or other quinolines.

PubMed Disclaimer

Similar articles

Cited by

References

    1. Arinaitwe, E., T. G. Sandison, H. Wanzira, A. Kahuru, J. Homsy, J. Kalamya, M. R. Kamya, N. Vora, B. Greenhouse, P. J. Rosenthal, J. Tappero, and G. Dorsey. 2009. Artemether-lumefantrine versus dihydroartemisinin-piperaquine for falciparum malaria: a longitudinal, randomized trial in young Ugandan children. Clin. Infect. Dis. 49:1629-1637. - PubMed
    1. Ashley, E. A., K. M. Lwin, R. Mcgready, W. H. Simon, L. Phaiphun, S. Proux, N. Wangseang, W. Taylor, K. Stepniewska, W. Nawamaneerat, K. L. Thwai, M. Barends, W. Leowattana, P. Olliaro, P. Singhasivanon, N. J. White, and F. Nosten. 2006. An open label randomized comparison of mefloquine-artesunate as separate tablets versus a new co-formulated combination for the treatment of uncomplicated multidrug-resistant falciparum malaria in Thailand. Trop. Med. Int. Health 11:1653-1660. - PubMed
    1. Barends, M., A. Jaidee, N. Khaohirun, P. Singhasivanon, and F. Nosten. 2007. In vitro activity of ferroquine (SSR 97193) against Plasmodium falciparum isolates from the Thai-Burmese border. Malar. J. 6:81. - PMC - PubMed
    1. Basco, L. K., and P. Ringwald. 2003. In vitro activity of piperaquine and other 4-aminoquinolines against clinical isolates of Plasmodium falciparum in Cameroon. Antimicrob. Agents Chemother. 47:1391-1394. - PMC - PubMed
    1. Bassat, Q., M. Mulenga, H. Tinto, P. Piola, S. Borrmann, C. Menendez, M. Nambozi, I. Valea, C. Nabasumba, P. Sasi, A. Bacchieri, M. Corsi, D. Ubben, A. Talisuna, and U. D'Alessandro. 2009. Dihydroartemisinin-piperaquine and artemether-lumefantrine for treating uncomplicated malaria in African children: a randomized, non-inferiority trial. PLoS One 4:7871. - PMC - PubMed

Publication types

MeSH terms